Abelacimab

BIOLOGICAL5 trials

Sponsors

Anthos Therapeutics, Inc., Novartis Pharmaceuticals

Conditions

Atrial Fibrillation (AF)Deep Venous ThrombosisPulmonary EmbolismStrokeVenous Thromboembolism

Phase 2

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

Active, not recruitingNCT04755283

Anthos Therapeutics, Inc.Atrial Fibrillation (AF), Stroke

Start: 2021-02-02End: 2028-12-29Updated: 2025-11-06

Phase 3

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

TerminatedNCT05171075

Anthos Therapeutics, Inc.Deep Venous Thrombosis, Pulmonary Embolism, Venous Thromboembolism

Start: 2022-09-27End: 2026-04-10Updated: 2026-04-17

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

TerminatedNCT05171049

Anthos Therapeutics, Inc.Deep Venous Thrombosis, Pulmonary Embolism, Venous Thromboembolism

Start: 2022-05-05End: 2026-02-04Updated: 2026-02-23

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

RecruitingNCT05712200

Anthos Therapeutics, Inc.Atrial Fibrillation (AF)

Start: 2022-12-27End: 2027-12-30Target: 2500Updated: 2026-07-13

Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation

Not yet recruitingNCT07739888

Novartis PharmaceuticalsAtrial Fibrillation (AF)

Start: 2027-12-30End: 2030-12-30Target: 2500Updated: 2026-07-31

Related Papers

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71

Blood2026-05-29

Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation

JAMA Cardiology2026-02-04

Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial

Circulation2025-06-233 citations

Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation

New England Journal of Medicine2025-01-2278 citations